| Trial ID: | L1595 |
| Source ID: | NCT02341547
|
| Associated Drug: |
A Biosimilar Epoetin Alfa
|
| Title: |
Effectiveness of a Biosimilar Epoetin Alfa in Stable 'End Stage Renal Failure'
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End Stage Renal Failure|Anaemia
|
| Interventions: |
DRUG: a Biosimilar Epoetin Alfa
|
| Outcome Measures: |
Primary: Mean change in haemoglobin levels, 12 weeks | Secondary: Adverse drug reactions and serious adverse effects, It is a composite end point, 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Penang Hospital, Malaysia
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
44
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2015-02
|
| Completion Date: |
2015-12
|
| Results First Posted: |
|
| Last Update Posted: |
2015-01-21
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT02341547
|
